Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Net Income: 2010-2025

Historic Net Income for Catalyst Pharmaceuticals (CPRX) over the last 15 years, with Sep 2025 value amounting to $52.8 million.

  • Catalyst Pharmaceuticals' Net Income rose 20.28% to $52.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $217.1 million, marking a year-over-year increase of 65.79%. This contributed to the annual value of $163.4 million for FY2024, which is 174.43% up from last year.
  • Catalyst Pharmaceuticals' Net Income amounted to $52.8 million in Q3 2025, which was up 1.30% from $52.1 million recorded in Q2 2025.
  • Catalyst Pharmaceuticals' Net Income's 5-year high stood at $56.7 million during Q1 2025, with a 5-year trough of -$30.8 million in Q3 2023.
  • Over the past 3 years, Catalyst Pharmaceuticals' median Net Income value was $40.8 million (recorded in 2024), while the average stood at $35.0 million.
  • Its Net Income has fluctuated over the past 5 years, first crashed by 235.24% in 2023, then spiked by 242.65% in 2024.
  • Quarterly analysis of 5 years shows Catalyst Pharmaceuticals' Net Income stood at $9.3 million in 2021, then skyrocketed by 173.62% to $25.5 million in 2022, then dropped by 9.82% to $23.0 million in 2023, then surged by 141.33% to $55.4 million in 2024, then increased by 20.28% to $52.8 million in 2025.
  • Its Net Income stands at $52.8 million for Q3 2025, versus $52.1 million for Q2 2025 and $56.7 million for Q1 2025.